Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
An elevated intrahepatic triglyceride (IHTG) is the classic feature of nonalcoholic fatty liver disease (NAFLD) and can be reduced by weight loss. It is...
An elevated intrahepatic triglyceride (IHTG) is the classic feature of nonalcoholic fatty liver disease (NAFLD) and can be reduced by weight loss. It is...
The main cause of liver diseases worldwide is metabolic associated fatty liver disease (MAFLD) and affects nearly a quarter of the global population. Mohammed...
Introduction Beta-blockers (β-blockers) are associated with intra-class variability including differences in their pharmacokinetic profile. Determination of intra-class pharmacokinetic as well as pharmacodynamic variability of...
In this article, we present to you data from a large retrospective cohort study that investigated the impact on mortality with β-blockers use versus...
Previous trials have reported that weight loss interventions help in improving biomarkers of non-alcoholic fatty liver disease (NAFLD). Due to lack of data, it...